Navigation Links
Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
Date:9/8/2011

September 7, 2011 (BRONX, NY) In 2004, the global community acted in earnest to address the HIV/AIDS epidemic in Africa. As a result, millions of Africans are now receiving the same advanced antiretroviral therapy (ART) that has long been available in the developed world. While research shows that AIDS death rates in Africa have stabilized, little is known about the actual deployment and circumstances of treatment.

A consortium led by Albert Einstein College of Medicine of Yeshiva University has received a $4 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to spearhead the Central Africa International Epidemiologic Databases to Evaluate AIDS (CA-IeDEA). CA-IeDEA researchers will work directly with the governments of Burundi and Cameroon, as well as with non-governmental organizations in Rwanda, to collect and analyze the data of nearly 40,000 patients on ART.

The International Epidemiologic Databases to Evaluate AIDS (IeDEA) is a research consortium established in 2005 to address the unique and evolving questions in global HIV/AIDS research through regional and intra-regional observational data. Kathryn Anastos, M.D., co-director of Einstein's Global Health Center and co-principal investigator of the grant, and her team will be among the global team analyzing and publishing on the data produced. One of only seven IeDEA centers around the world, CA-IeDEA will create a robust and flexible database that will enable researchers to examine the real-world practice and results of ART including its impact on reducing cancer and interactions of HIV with other major, deadly diseases that afflict the region, such as malaria.

"Central Africa is a unique region that presents its own set of challenges for effective HIV/AID
'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Einstein scientists find crucial molecule involved in spread of breast cancer
2. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
3. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
4. Feinstein scientists identify abnormal disease pathway in dystonia
5. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
6. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
7. ALBERT EINSTEIN COLLEGE OF MEDICINE HELPS ADDRESS NEED FOR IMPROVED CANCER CARE IN RURAL AMERICA
8. Feinstein Institute to share $5M US Department of Defense grant
9. Einstein scientist awarded $4 million to develop genetic strategy to combat tuberculosis
10. Einstein awarded NIH grant to study drug-resistant TB
11. NIH awards $10M to Einstein for diabetes research
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... Eagerly embracing intended parents around the globe, ... offers the top male infertility programs — run by ... network of IVFinMexico.com continues to shape modern ... female and male infertility, advanced research and education. , ... eminently set by company CEO and Founder Tolga Umar ...
(Date:8/22/2014)... 2014 Mueller Sports Medicine is excited ... exciting new product that provides non-drug instant relief for ... while you heal. The package includes 7 days of ... technology – it is not kinesiology tape. It’s made ... System for Plantar Fasciitis is a breakthrough in ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
Breaking Medicine News(10 mins):Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 2Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 3Health News:Mexico Now Offers Top Program for Couples Suffering from Male Infertility 4Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... birth but develop accelerated head growth between six and ... onset of many behaviors that enable physicians to diagnose ... University of Washingtons Autism Center., The study also indicates ... have the early onset form of autism as well ...
... Store,s Gift of Mobility Fulfills Dreams of Terminally Ill,Stage Performer, ... his life in the public eye - whether he was ... or appearing in,television commercials. But two years ago, cancer robbed ... past year. To fulfill his,dream to get outside again, The ...
... BOCA RATON, Fla., Jan. 30 Spirit of ... bidding for the Spirit of Women,Celebrity Red Shoe ... will benefit several health,organizations, including the National Stroke ... for auction February 5,through February 14 were autographed ...
... Web address on all TV ads to report adverse,reactions, ... ads that sell the "good news" about prescription drugs,but ... on a petition to the FDA demanding the agency ... medications., The citizens, petition requests the Food and ...
... LANSING, Jan. 30 A report issued today ... policy consultancy,based in Washington, D.C., confirms that Blue ... million to the people of Michigan in 2007 ... to improve access to,health coverage at affordable prices. ...
... known to doctors as a hormone that boosts red-blood-cell production. ... PhD, an ophthalmologist at Children,s Hospital Boston, shows it also ... The findings not only add a new function to the ... prescribing it to patients with diseases affected by abnormal blood-vessel ...
Cached Medicine News:Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Former Actor has Mobility Restored With Power Wheelchair Gift From The Scooter Store 2Health News:Celebrities Encourage Women to Take Steps for Heart Health Through Online Red Shoe Charity Auction 2Health News:Petition Asks FDA to Make it Easier for Patients to Report Side Effects from Prescription Drugs 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 2Health News:Examination by National Expert Shows Blue Cross Blue Shield of Michigan's Social Mission Contributions Totaled at Least $391 Million in 2007 3Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 2014  eRelevance Corporation ( www.erelevancecorp.com ), a ... it has completed integration with Nextech, a popular ... and Dermatology practices. "Integration allows our ... practices using Nextech," stated Bob Fabbio , ... from the EMR we are able to automatically ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3
... of trial triggers $10 million milestone payment to PharmassetPRINCETON, ... VRUS ) and Roche (Roche SWX: RO, ROG; Pink ... been dosed in a Phase IIb study of R7128, ... the treatment of chronic hepatitis C (HCV). The trial ...
... to Initiate in 2010 for BlinatumomabNEW YORK, April 24 ... biopharmaceutical company developing novel, proprietary antibodies for the treatment ... R&D Day for investors and financial analysts at The ... highlighted significant areas of development across Micromet,s BiTE antibody ...
Cached Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4